Glucagon-like peptide 1 receptor agonists, more commonly known as GLP-1 medications, have dominated headlines for their ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filling in the gaps.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling ...

Ilant estimates that behavioral therapy can help many people lose up to 5% of their weight, anti-obesity medications can help ...

Some fear weight-loss stocks are approaching bubble territory, but this incumbent player continues to prove its worth ...

Originally approved to help with excess weight and obesity, Wegovy and Ozempic, have become synonymous with weight loss fads.

New drugs from public and private companies are expected to saturate the obesity drug market. Novo Nordisk and Eli Lilly are currently dominating the weight ... of the total GLP-1 market, which ...

The U.S. Food and Drug Administration said Eli Lilly's diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in expanding ...

“Our independent committee found this medicine to be both effective and good value for money. Its use will help people living ...

It was an impressive performance by Dubois, who after suffering a KO loss to Oleksandr Usyk ... are moving to a different weight class will be ranked in that new division, if warranted, only ...

President Joe Biden praised the U.S. and Israel militaries for defeating the barrage and warned, “Make no mistake, the United States is fully, fully supportive of Israel.” ...